Clear cell renal cell carcinoma(ccRCC)is the most common and aggressive subtype of renal cancer.Despite advances in treatment,its prognosis remains poor.In this study,we developed a lipid immune score(LIS)based on six...Clear cell renal cell carcinoma(ccRCC)is the most common and aggressive subtype of renal cancer.Despite advances in treatment,its prognosis remains poor.In this study,we developed a lipid immune score(LIS)based on six genes(ADAM8,IQGAP2,SLC16A12,PYCR1,TOX3,and LRRC19)involved in lipid metabolism and immune response.These genes are differentially expressed in ccRCC and are associated with tumor progression and patient survival.The LIS shows potential for improving diagnosis,prognosis evaluation,and identifying therapeutic targets in ccRCC.Although promising,further validation and clinical standardization are needed.展开更多
文摘Clear cell renal cell carcinoma(ccRCC)is the most common and aggressive subtype of renal cancer.Despite advances in treatment,its prognosis remains poor.In this study,we developed a lipid immune score(LIS)based on six genes(ADAM8,IQGAP2,SLC16A12,PYCR1,TOX3,and LRRC19)involved in lipid metabolism and immune response.These genes are differentially expressed in ccRCC and are associated with tumor progression and patient survival.The LIS shows potential for improving diagnosis,prognosis evaluation,and identifying therapeutic targets in ccRCC.Although promising,further validation and clinical standardization are needed.
